Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
Author:
Affiliation:
1. Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
2. General Practice Department, Zhongshan Hospital, Fudan University, Shanghai, China
Funder
Shanghai Sailing Program
Publisher
Informa UK Limited
Subject
Oncology,Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1457600
Reference45 articles.
1. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2. Meta-analysis of Epidermal Growth Factor Receptor and KRAS Gene Status between Primary and Corresponding Metastatic Tumours of Non-small Cell Lung Cancer
3. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Novel Protozoa Parasite-Derived Protein Adjuvant Is Effective in Immunization with Cancer Cells to Activate the Cancer-Specific Protective Immunity and Inhibit the Cancer Growth in a Murine Model of Colorectal Cancer;Cells;2024-01-06
2. LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8 + T cells for improving anti-PD-1 antibody therapy;OncoImmunology;2023-12-14
3. Probing the origins of programmed death ligand-1 inhibition by implementing machine learning-assisted sequential virtual screening techniques;Molecular Diversity;2023-07-20
4. Identification of immune subtypes and response prediction to immune-checkpoint inhibitors for MDM4 gain/amplification luminal A type breast cancer;2023-05-23
5. Real-World Data of Nivolumab and Pembrolizumab in Platinum Refractory Advanced Non-Small Cell Lung Cancer: Potential Practical Predictors of Treatment;International Journal of Hematology and Oncology;2022-04-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3